Repros Adds Marketing and Commercialization Expertise to Board of Directors

Repros Adds Marketing and Commercialization Expertise to Board of Directors

THE WOODLANDS, Texas, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced it has added Michael Suesserman to the
Company's Board of Directors.

Michael Suesserman is currently Managing Director, Cello Health Consulting,
providing advisory services to the global life sciences industry. Mike brings
over two decades of experience in launching, building, and developing
pharmaceutical marketing platforms, including those for the megabrands Lipitor
and Viagra.

Mike's breadth of experience in commercializing pharmaceuticals spans the
entire product lifecycle, including portfolio prioritization, product
development, US and Global product management, life-cycle extension as well as
reimbursement and market access. He spent 18 years at Pfizer, in roles of
increasing responsibility. He was the US and then Global Team Leader for
Lipitor, was responsible for the global urology franchise and also held the
position of VP, Managed Markets Group in the US.

In addition to overall commercial expertise, Mike has extensive experience in
a number of therapeutic areas, particularly urology. He was responsible for
the commercial development of Pfizer's Sexual Health franchise strategy,
re-positioning and re-launching Viagra in the face of the global introductions
of Cialis and Levitra, and creating access and formulary placement for Detrol
LA in the US.

Mike holds an MBA from Kelley School of Business at Indiana University and
earned his Bachelor's degree in Economics from Clark University.

Joseph Podolski, President and CEO of Repros commented, "We are fortunate to
have Mike join the Repros Board of Directors. His unique skill set provides
Repros with important sales and marketing insight to help us develop our
strategy to maximize shareholder returns for our lead product Androxal." He
further noted, "Assuming Androxal attains US FDA approval, we believe it has
the potential of the 'megabrands' Mike has been intimately associated with,
driving these drugs to commercial success."

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to have success in the clinical
development of its technologies, the reliability of interim results to predict
final study outcomes, the ability to protect its intellectual property rights
and such other risks which are identified in the Company's most recent Annual
Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q.
These documents are available on request from Repros Therapeutics or at
www.sec.gov. Repros disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

CONTACT: Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931
         thoffmann@troutgroup.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.